HARMONY BIOSCIENCES HOLDINGS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $0.00.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $408.00K, a 98.63% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $29.70M, a 78.07% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2022 was $408.00K, a 98.63% decline from fiscal 2021.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2021 was $29.70M, a 78.07% decline from fiscal 2020.
- HARMONY BIOSCIENCES HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2020 was $135.44M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $408.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $408.00K 10-Q · filed 2023-10-31 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $29.70M 10-K · filed 2024-02-22 |
| 2021-09-30 | $29.70M 10-Q · filed 2022-11-01 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $135.44M 10-K · filed 2023-02-21 |
| 2020-09-30 | $135.44M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |